![[Initiatives] Two new centers open in Paris for a clinical trial on Alzheimer’s disease](https://regenlife.com/wp-content/uploads/2026/03/logo_esteval.jpg){kind=logo}
Since 17 March, the Hospices Civils de Lyon (HCL) have been testing a light-based technology that could slow the progression of Alzheimer’s disease. The Montpellier-based company Regenlife is conducting a clinical trial at the Charpennes geriatric hospital (Villeurbanne) to evaluate a non-invasive medical device that combines a headset and an abdominal belt capable of slowing cognitive decline in patients.
The team aims to offer a treatment option to people who currently have no access to any state-funded treatment. Guillaume Blivet, co-founder of Regenlife, says it is “a groundbreaking innovation with no equivalent on the market”
Light reduces brain inflammation
It uses photobiomodulation, a technology capable of emitting red and infrared light that penetrates tissue to stimulate cellular activity, a key mechanism for preventing the progression of the disease. “The light activates biological processes and protects neurons by reducing inflammation,” explains Guillaume Blivet.
